BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18381562)

  • 1. Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel.
    Hancox JC; James AF
    Mol Pharmacol; 2008 Jun; 73(6):1592-5. PubMed ID: 18381562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topological mapping of the asymmetric drug binding to the human ether-à-go-go-related gene product (HERG) potassium channel by use of tandem dimers.
    Myokai T; Ryu S; Shimizu H; Oiki S
    Mol Pharmacol; 2008 Jun; 73(6):1643-51. PubMed ID: 18326583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.
    Perrin MJ; Kuchel PW; Campbell TJ; Vandenberg JI
    Mol Pharmacol; 2008 Nov; 74(5):1443-52. PubMed ID: 18701618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
    Imai YN; Ryu S; Oiki S
    J Med Chem; 2009 Mar; 52(6):1630-8. PubMed ID: 19260734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular determinants of high-affinity drug binding to HERG channels.
    Mitcheson JS; Perry MD
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
    Zachariae U; Giordanetto F; Leach AG
    J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY; Yang SJ
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
    Karczewski J; Wang J; Kane SA; Kiss L; Koblan KS; Culberson JC; Spencer RH
    Biochem Pharmacol; 2009 May; 77(10):1602-11. PubMed ID: 19426697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
    Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
    Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
    Wang L; Wible BA; Wan X; Ficker E
    J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
    Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
    J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.
    Ekins S; Balakin KV; Savchuk N; Ivanenkov Y
    J Med Chem; 2006 Aug; 49(17):5059-71. PubMed ID: 16913696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
    Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
    Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies.
    Masetti M; Cavalli A; Recanatini M
    J Comput Chem; 2008 Apr; 29(5):795-808. PubMed ID: 17926340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization.
    Sintra Grilo L; Carrupt PA; Abriel H; Daina A
    Eur J Med Chem; 2011 Aug; 46(8):3486-98. PubMed ID: 21624711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels.
    Zhang DY; Wang Y; Lau CP; Tse HF; Li GR
    Cell Signal; 2008 Oct; 20(10):1815-21. PubMed ID: 18617000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
    Hancox JC; McPate MJ; El Harchi A; Zhang YH
    Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of sevoflurane and propofol on QT interval and heterologously expressed human ether-a-go-go related gene currents in Xenopus oocytes.
    Yamada M; Hatakeyama N; Malykhina AP; Yamazaki M; Momose Y; Akbarali HI
    Anesth Analg; 2006 Jan; 102(1):98-103. PubMed ID: 16368812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel structure-based virtual screening model for the hERG channel blockers.
    Du L; Li M; You Q; Xia L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM; Ecker GF
    Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.